肺癌患者检测血清可溶性Ⅰ型细胞间黏附分子的临床意义  

Clinical Significance of Detection of Serum Soluble Intercellular Adhesion Molecule-1 in Patients with Lung Cancer

作　　者：朱建光[1] 陈灵芝[1] 黄瑞燕[1] 李骏白[1] 陈理达[1] 陈奋杰[1] 潘峰[1] 

机构地区：[1]温州市第二人民医院,浙江温州325000

出　　处：《肿瘤学杂志》2005年第3期188-190,共3页Journal of Chinese Oncology

基　　金：浙江省温州市科技发展计划项目(S2001A44)

摘　　要：[目的]探讨肺癌患者全身化疗前后血清可溶性Ⅰ型细胞间黏附分子(sICAM鄄1)水平的动态变化及其与疗效的关系,同时分析肺癌根治术后患者血清sICAM鄄1水平。[方法]晚期肺癌或术后复发患者40例,以酶联免疫吸附法检测其化疗前血清sICAM鄄1水平,并对其中初治患者23例检测其第一和第二周期化疗后血清sICAM鄄1水平并评价近期疗效,分析两者之间关系;同时检测21例肺癌根治术后患者和27例健康体检者的血清sICAM鄄1水平作为对照,并进行比较分析。[结果]治疗组血清sICAM鄄1水平(526.6±213.9ng/ml)显著高于健康对照组(281.3±109.8ng/ml,P<0.001);初治患者中治疗有效者化疗第一周期后血清sICAM鄄1水平即有所降低(P>0.05),化疗第二周期后则显著下降(P<0.01);治疗无效者初无显著变化(P>0.05),继而上升(P<0.05);肺癌术后对照组的血清sICAM鄄1水平(380±140.9ng/ml)亦显著高于健康对照组(P<0.01),而低于治疗组(P<0.01)。[结论]血清sICAM鄄1水平有可能作为肺癌患者化疗疗效评估和发现术后复发的较早参考指标。Purpose]To assess the relationship between the dynamic changes of serum level soluble intercellular adhesion molecule-1(sICAM-1) and the effect of intravenous chemotherapy in patients with lung cancer, and to investigate the serum levels of sICAM-1 after radical surgery in lung cancer patients. [Methods] Forty cases with advanced or recurrent lung cancer(palliative chemotherapy group) received chemotherapy. Serum sICAM-1 levels were measured by enzyme-linked immunosorbent assay before chemotherapy and after 1, 2 cycle of chemotherapy. The relationship between the serum levels of sICAM-1 before and after chemotherapy, and the effects of chemotherapy in 23 cases who had no prior chemotherapy were analysed. The serum levels of sICAM-1 in 21 lung cancer patients after radical excision and meanwhile 27 healthy controls were measured as control. [Results] The serum levels of sICAM-1 in the palliative chemotherapy group (526.6ng/ml±213.9ng/ml) were significantly higher than those in the healthy control group (281.3ng/ml±109.8ng/ml, P<0.001). In the patients who had no prior chemotherapy and were effective after chemotherapy, the serum level of sICAM-1 decreased after 1 cycle (P<0.05) and markedly dripped down after 2 cycles (P<0.01), but no significant change after cycle 1 (P<0.05) and marked increase after 2 cycle(P<0.05) was found in no response cases. The serum sICAM-1 level in the postoperative cases (380ng/ml±140.9ng/ml) were significantly higher than that in the healthy controls (P<0.01) and lower than that in the palliative chemotherapy group(P<0.01).[Conclusion]Serum levels of sICAM-1 is possible to become a marker to evaluate efficacy of chemotherapy and to detect recurrence for lung cancer patients.

关 键 词：肺肿瘤 细胞黏附分子 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤]